<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887506</url>
  </required_header>
  <id_info>
    <org_study_id>TAVT45C02</org_study_id>
    <secondary_id>2020-005611-46</secondary_id>
    <nct_id>NCT04887506</nct_id>
  </id_info>
  <brief_title>TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer</brief_title>
  <official_title>Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC &amp; mCRPC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tavanta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tavanta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of a new formulation of&#xD;
      an existing drug product called TAVT-45 in patients with metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3 randomized, open-label study to evaluate the pharmacodynamic effect and&#xD;
      safety profile of TAVT-45 compared to Zytiga (reference abiraterone acetate formulation,&#xD;
      hereafter referred to as R-AA) in patients with mCSPC and mCRPC. Randomization will be&#xD;
      stratified by prostate cancer population (CSPC vs CRPC) and baseline testosterone (&lt;10 vs ≥&#xD;
      10 ng/dL). Patients will be treated for 84 days and randomized into one of two groups in a&#xD;
      1:1 ratio:&#xD;
&#xD;
        -  TAVT-45: Administered twice daily as 1 x sachet containing TAVT-45 (250 mg abiraterone&#xD;
           acetate) + Prednisone (5 mg once or twice daily, depending on prostate cancer&#xD;
           population)&#xD;
&#xD;
        -  R-AA: Administered once daily as (2 x 500 mg Zytiga tablets) + Prednisone (5 mg once or&#xD;
           twice daily, depending on prostate cancer population)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Testosterone Levels</measure>
    <time_frame>Average over Day 9 and Day 10</time_frame>
    <description>Blood samples collected to measure serum testosterone in order to demonstrate equivalent pharmacodynamic effect between TAVT-45 and reference abiraterone acetate (R-AA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With PSA-50 Response</measure>
    <time_frame>Over 84 days</time_frame>
    <description>Blood samples collected to measure prostate-specific antigen (PSA). The PSA-50 response is defined as a decrease of ≥ 50% in PSA levels from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Levels</measure>
    <time_frame>Days 28, 56 and 84</time_frame>
    <description>Blood samples collected to measure serum testosterone levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With PSA-50 Response</measure>
    <time_frame>Days 28, 56, and 84</time_frame>
    <description>Blood samples collected to measure PSA in order to determine PSA-50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Levels</measure>
    <time_frame>Days 28, 56, and 84</time_frame>
    <description>Blood samples collected to measure PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations of abiraterone</measure>
    <time_frame>Days 9, 28, 56, and 84</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone (trough sample to be collected before next dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of AUC</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone in a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of Cmax</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone in a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of Cmin</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone in a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of Tmax</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone in a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of Rac</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone in a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of t1/2</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>Blood samples collected to measure plasma concentrations of abiraterone in a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Metastatic Castration-sensitive Prostate Cancer</condition>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TAVT-45</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVT-45 administered twice daily as a 1 x sachet containing TAVT-45 (250 mg abiraterone acetate) + Prednisone (5mg once or twice daily, depending on prostate cancer population). TAVT-45 administered approximately every 12 hours without respect to food. Patients treated for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference abiraterone acetate (Zytiga®) - R-AA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) administered once daily as (2 x 500mg Zytiga tablets) + Prednisone (5mg once or twice daily, depending on prostate cancer population). R-AA administered once daily either ≥ 1 hour before or ≥ 2 hours after a meal. Patients treated for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAVT-45</intervention_name>
    <description>250 mg abiraterone acetate granules for oral suspension in a sachet, administered twice daily.</description>
    <arm_group_label>TAVT-45</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zytiga</intervention_name>
    <description>500 mg tablet, administered twice daily.</description>
    <arm_group_label>Reference abiraterone acetate (Zytiga®) - R-AA</arm_group_label>
    <other_name>Abiraterone Acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>mCSPC patients will receive 5 mg orally once daily. mCRPC patients will receive 5 mg orally twice daily.</description>
    <arm_group_label>Reference abiraterone acetate (Zytiga®) - R-AA</arm_group_label>
    <arm_group_label>TAVT-45</arm_group_label>
    <other_name>Encorton</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained prior to any study-related procedure being performed&#xD;
&#xD;
          2. Male patients at least 18 years of age or older at time of consent&#xD;
&#xD;
          3. Pathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          4. Ongoing therapy with a gonadotropin releasing hormone (GnRH) agonist or antagonist&#xD;
             (unless patient has already had a bilateral orchiectomy) AND serum testosterone level&#xD;
             &lt;50 ng/dL at screening&#xD;
&#xD;
          5. Have either metastatic CSPC or metastatic CRPC (per protocol definitions).&#xD;
&#xD;
          6. The following prior treatments and/or surgery for prostate cancer are allowed:&#xD;
&#xD;
               1. CSPC:&#xD;
&#xD;
                    -  Up to 90 days of androgen deprivation therapy (ADT) with&#xD;
                       gonadotropin-releasing hormone (GnRH) agonists/antagonists or orchiectomy&#xD;
                       with or without concurrent anti-androgens prior to patients' randomization&#xD;
                       is permitted&#xD;
&#xD;
                    -  Patients may have one course of palliative radiation or surgical therapy to&#xD;
                       treat symptoms resulting from metastatic disease (e.g., impending cord&#xD;
                       compression or obstructive symptoms) if administered prior to randomization&#xD;
&#xD;
                    -  Radiation or surgical therapy that was not initiated 4 weeks after the start&#xD;
                       of ADT or orchiectomy&#xD;
&#xD;
               2. CRPC:&#xD;
&#xD;
                    -  Previous chemotherapy with docetaxel for metastatic disease with treatment&#xD;
                       completed at least 1 year prior to enrolment&#xD;
&#xD;
          7. Discontinuation of flutamide or nilutamide, and other anti-androgens prior to the&#xD;
             start of study medication; discontinuation of bicalutamide prior to start of study&#xD;
             medication&#xD;
&#xD;
          8. Discontinuation of strong CYP3A4 inducers at prior to start of study medication&#xD;
&#xD;
          9. Discontinuation of radiotherapy prior to start of study medication&#xD;
&#xD;
         10. Discontinuation of herbal supplements at least 4 weeks prior to the first dose of&#xD;
             study medication and for the duration of the trial.&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at screening&#xD;
&#xD;
         12. Normal organ function with acceptable initial laboratory values within the screening&#xD;
             period:&#xD;
&#xD;
               -  ANC: ≥ 1,500/μl&#xD;
&#xD;
               -  Albumin: ≥ 3.0g/dL&#xD;
&#xD;
               -  Hemoglobin: ≥ 9g/dL&#xD;
&#xD;
               -  Platelet count: ≥ 100,000/μl&#xD;
&#xD;
               -  Serum Creatinine: ≤ 3.0 x the institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Potassium: ≥ 3.5 mmol/L (within institutional normal range)&#xD;
&#xD;
               -  Bilirubin: ≤ 1.5 ULN (unless documented Gilbert's disease)&#xD;
&#xD;
               -  SGOT (AST): ≤ 2.5 x ULN&#xD;
&#xD;
               -  SGPT (ALT): ≤ 2.5 x ULN&#xD;
&#xD;
         13. Life expectancy of at least 6 months at screening&#xD;
&#xD;
         14. Patients engaged in sex with women of child-bearing potential agree to use a condom&#xD;
             plus another effective contraception method. Patients agree to use a condom when&#xD;
             engaged in any sexual activity, including sex with a pregnant woman. These&#xD;
             restrictions will apply from the time informed consent is provided until 3 weeks after&#xD;
             the last dose of study medication is taken.&#xD;
&#xD;
         15. Patient is willing and able to comply with all protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For mCSPC patients: any prior pharmacotherapy, radiation therapy, or surgery for&#xD;
             metastatic prostate cancer not specified as allowable treatment in Inclusion Criterion&#xD;
             6. For example, prior therapy with apalutamide or enzalutamide is prohibited as well&#xD;
             as therapy with an investigational agent as described in Exclusion Criterion 16.&#xD;
&#xD;
          2. For mCRPC patients:&#xD;
&#xD;
               -  Prior treatment with abiraterone or enzalutamide is prohibited&#xD;
&#xD;
               -  Previous chemotherapy is prohibited with exception of docetaxel treatment as&#xD;
                  specified in the inclusion criteria 6.&#xD;
&#xD;
          3. Initiation of bisphosphonate or denosumab therapy within 4 weeks prior to the start of&#xD;
             study drug/reference product. Patients who are on a stable dose of these medications&#xD;
             for at least 4 weeks at the time of starting study drug/reference product will be&#xD;
             eligible.&#xD;
&#xD;
          4. Therapy with estrogen within 4 weeks prior to the start of study drug&#xD;
&#xD;
          5. Use of systemic glucocorticoids equivalent to &gt;10 mg prednisone daily. Patients who&#xD;
             have discontinued or reduced dosing to the equivalent of ≤ 10 mg prednisone daily&#xD;
             within 14 days prior to the start of study drug are eligible&#xD;
&#xD;
          6. Known, symptomatic metastases to the brain or central nervous system involvement&#xD;
             (patients with asymptomatic and neurologically stable disease for the past 4 weeks&#xD;
             will be permitted)&#xD;
&#xD;
          7. History of adrenal gland dysfunction defined as requiring treatment for adrenal&#xD;
             insufficiency&#xD;
&#xD;
          8. History of other malignancy within the previous 2 years (no longer being actively&#xD;
             treated), with the exceptions of basal cell carcinoma, nonmuscle invasive bladder&#xD;
             cancer that has been treated and is under surveillance, or other in-situ cancers with&#xD;
             a low likelihood of recurrence&#xD;
&#xD;
          9. Major surgery within 4 weeks prior to the start of study drug&#xD;
&#xD;
         10. Known gastrointestinal disease or condition that could impair absorption inclusive of&#xD;
             gastrocolic fistula, gastroenterostomy, biliary obstruction, cirrhosis, chronic&#xD;
             pancreatitis or pancreatic cancer, cystic fibrosis, lactate deficiency, amyloidosis,&#xD;
             celiac disease, Crohn's disease, radiation enteritis, intestinal resection, and&#xD;
             history of bariatric surgery&#xD;
&#xD;
         11. Known history of human immunodeficiency virus or seropositive test for hepatitis C&#xD;
             virus (HCV) or hepatitis B surface antigen (HBsAg) (note: HCV patients with&#xD;
             undetectable viral load will be eligible)&#xD;
&#xD;
         12. Poorly controlled diabetes, defined as HbA1c &gt; 8% within the past 12 months&#xD;
&#xD;
         13. Uncontrolled hypertension at screening&#xD;
&#xD;
         14. History of New York Heart Association class III or IV heart failure&#xD;
&#xD;
         15. Serious concurrent illness, including psychiatric illness, that could interfere with&#xD;
             study participation&#xD;
&#xD;
         16. Receipt of another investigational agent within 4 weeks or 5 x the treatment&#xD;
             half-life, whichever is longer, of treatment start.&#xD;
&#xD;
         17. Known hypersensitivity or allergy to abiraterone acetate, prednisone or any excipients&#xD;
             in the study drugs&#xD;
&#xD;
         18. In the opinion of the investigator, participation in the trial would prevent the&#xD;
             patient from receiving local standard-of-care treatment for metastatic prostate&#xD;
             cancer, if clinically indicated, after completion of the trial&#xD;
&#xD;
         19. Other condition which, in the opinion of the Investigator, would preclude&#xD;
             participation in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Prescott, MBChB, MFPM</last_name>
    <role>Study Director</role>
    <affiliation>TMC Pharma Services Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominic Capone</last_name>
    <phone>+16093100378</phone>
    <email>dominic.capone@tavanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology Centers of Alabama, 3485 Independence Drive</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle Hamilton, M.D</last_name>
      <phone>205-445-0124</phone>
      <email>Jhamilton@urologyal.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Dunshee, M.D</last_name>
      <phone>520-742-9777</phone>
      <email>doccd@uasapc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Marotte, MD</last_name>
      <phone>501-219-8900</phone>
      <phone_ext>2002</phone_ext>
      <email>JMarotte@arkansasurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tower Urology, 8635 West 3rd Street, Suite 1 West Los Angeles,</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Josephson, M.D</last_name>
      <phone>310-854-9898</phone>
      <phone_ext>168</phone_ext>
      <email>josephsond@towerurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates Medical Group, 489 East 21st Street</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franklin Chu, M.D</last_name>
      <phone>909-882-2973</phone>
      <email>fmcsbu@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Urology Centre of Colorado, 2777 Mile High Stadium Circle,</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Karsh, M.D</last_name>
      <phone>303-421-5783</phone>
      <email>lkarsh@tucc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manatee Medical Research Institute, 200 3rd Avenue West Suite 210</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Miller, M.D</last_name>
      <phone>941-524-8572</phone>
      <email>Admin@MMRInstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Idaho Urologic Institute, 2855 E Magic View Drive</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Waldmann, MD</last_name>
      <phone>208-639-4884</phone>
      <email>twaldmann@idurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Urology</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Bailen, MD</last_name>
      <phone>812-206-8161</phone>
      <email>jbailen@1sturology.com</email>
    </contact>
    <investigator>
      <last_name>James Bailen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Levin, MD</last_name>
      <phone>443-471-3309</phone>
      <email>rlevin@chesuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth M Kernen, MD</last_name>
      <phone>248-740-0670</phone>
      <email>kernenk@michiganurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice, PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jed Kaminetsky, MD</last_name>
      <phone>212-480-3333</phone>
      <email>jckaminetsky@manhattanmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Given</last_name>
      <email>rgiven@urologyfva.net</email>
    </contact>
    <investigator>
      <last_name>Robert Given, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Debrecen, Oncology Clinic, Nagyerdei Körút 98</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Arkosy, M.D</last_name>
      <phone>+36 52 411 717</phone>
      <phone_ext>54330</phone_ext>
      <email>arkosy.peter@med.unideb.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyczno-Lecznicze &quot;Gammed&quot;ac Lelechowska 5</name>
      <address>
        <city>Warszawa</city>
        <state>Masovia</state>
        <zip>02-351</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Kolasińska Cwikla, M.D</last_name>
      <phone>+48 601359657</phone>
      <email>adkolasinska@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>In-Vivo Sp. Z O.O.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-048</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Piasecki, MD</last_name>
      <phone>+48 501109918</phone>
      <email>piotr.piasecki@in-vivo.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZOZ Heureka</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Szalecki, MD</last_name>
      <phone>+48227501610</phone>
      <email>pawelszalecki@heureka.net.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <state>Av. Reyes Católicos 2</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imanol Martínez Salas, M.D</last_name>
      <phone>+34 91 550 4800</phone>
      <phone_ext>3146</phone_ext>
      <email>imanol.martinez@quironsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Althaia Xarxa Assistencial Universitaria de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Domenech, M.D</last_name>
      <phone>+34 938 73 25 50</phone>
      <email>mdomenech@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico HM Clara Campal</name>
      <address>
        <city>Madrid</city>
        <state>Calle De Oña 10</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Francisco Rodríguez Moreno, M.D</last_name>
      <phone>+34 91 756 7800</phone>
      <phone_ext>4887/4813</phone_ext>
      <email>jfrodriguez@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Parc Taulí</name>
      <address>
        <city>Barcelona</city>
        <state>Sabadell</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gallardo, M.D</last_name>
      <phone>+34 93 724 0084</phone>
      <email>egallardo@tauli.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Pablo Maroto</last_name>
      <phone>+34 96 556 5638</phone>
      <email>jmaroto@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellano, MD</last_name>
      <phone>+34 91 390 8307</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Univ. Hospital, Dept. of Urology</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Stranne, M.D</last_name>
      <phone>+46-31-3421000</phone>
      <email>johan.stranne@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västmanland Hospital Västerås, Dept. of Oncology</name>
      <address>
        <city>Västerås</city>
        <zip>SE-721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raya Natik, M.D</last_name>
      <phone>+46 (0)21 17 30 00</phone>
      <email>raya.natik.ibrahim@regionvastmanland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital, Lowes Bridge</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lydon, M.D</last_name>
      <phone>01803 656623</phone>
      <email>anna.lydon@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital, Sandford Rd</name>
      <address>
        <city>Cheltenham</city>
        <state>Gloucestershire</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Grant, M.D</last_name>
      <phone>0300 4223510</phone>
      <email>warren.grant@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, Pond Street,</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Needleman, M.D</last_name>
      <phone>0207 8302169</phone>
      <email>sarah.needleman@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre, 1053 Great Western Rd,</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bala Venugopal, MD</last_name>
      <phone>0141 3017064</phone>
      <email>Balaji.Venugopal@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital, Egerton Rd,</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chee Goh, M.D</last_name>
      <phone>01737 768511</phone>
      <email>c.goh@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.tavanta.com/pipeline/tavt-45-for-prostate-cancer/</url>
    <description>Sponsors website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Informed Consent Form:&#xD;
The health information that may be used and disclosed includes:&#xD;
All information collected during the research described in the Informed Consent Form for the study; and&#xD;
Health information in my medical records that is relevant to the study.&#xD;
The Providers may disclose health information in my medical records to:&#xD;
Researchers;&#xD;
The Sponsor of the study and its agents and contractors; and&#xD;
Representatives of government agencies, Advarra IRB, and other persons who watch over the safety, effectiveness, and conduct of research.&#xD;
The Researchers may:&#xD;
Use and share patient health information among themselves, with the Sponsor, and with other participating researchers and laboratories to conduct the study; and&#xD;
Disclose health information to representatives of government agencies, review boards</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The sponsor will store the data for at least 30 years after completion; or discontinuation of the study; or for at least 30 years after the granting of the last marketing authorization until there are no more pending; or contemplated marketing applications; or for at least 30 years after formal discontinuation of the clinical development of the study drug, or are scheduled for submission</ipd_time_frame>
    <ipd_access_criteria>The Sponsor will ensure that its affiliated companies or its third-party data processors that analyze data on behalf of the Sponsor treat all patient data in a confidential manner and in accordance with 'The Health Insurance Portability and Accountability Act of 1996' (HIPAA).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

